

TEST CHANGE

Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

2009288, PAIN HYB 2

Specimen Requirements:

Patient Preparation: Information on the patient's current medications must be submitted with the order. Include trade name, generic name, dosing frequency and date of last dose, if known. Alternatively, please indicate if no prescription medication or drugs are being taken.

Collect: Random urine.

Specimen Preparation: Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)

Transport Temperature: Refrigerated

Unacceptable Conditions: Specimens exposed to repeated freeze/thaw cycles.

Remarks:

Stability: Ambient: 1 week (Clonazepam may be unstable at ambient condition beyond three days); Refrigerated: 1 month; Frozen: 1 month

Methodology: Qualitative Liquid Chromatography-Tandem Mass Spectrometry/Enzyme Immunoassay/Quantitative Spectrophotometry

Performed: Sun-Sat

Reported: 1-4 days

Note: Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.

CPT Codes: 80326; 80347; 80364; 80355; 80307 (Alt code: G0481)

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

~~Effective February 16, 2021~~

Drugs covered and range of cutoff concentrations. Note: Some drugs are identified based on the presence of unique drug metabolites not listed below.

| Drugs/Drug Classes | Range of Cutoff Concentrations |
|---|--------------------------------|
| Barbiturates | 200 ng/mL |
| Benzodiazepine-like: alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem | 20 - 60 ng/mL |
| Cannabinoids (11-nor-9-carboxy-THC) | 50 20 ng/mL |
| Ethyl Glucuronide | 500 ng/mL |
| Muscle Relaxant(s): carisoprodol, meprobamate | 100 ng/mL |
| Opiates/Opioids: buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, | 2-200 ng/mL |

| | | |
|---|--------------|--|
| morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol | | |
| GABA analogues: Gabapentin, pregabalin | 3,000 ng/mL | |
| Phencyclidine (PCP) | 25 ng/mL | |
| Stimulants: amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine | 50-200 ng/mL | |